Epilepsy is a serious neurological disorder that affects around 50 million people worldwide. Almost 30% of epileptic patients suffer from pharmacoresistance, which is associated with social isolation, dependent behaviour, low marriage rates, unemployment, psychological issues and reduced quality of life. Currently available antiepileptic drugs have a limited efficacy, and their negative properties limit their use and cause difficulties in patient management. Antiepileptic drugs can provide only symptomatic relief as these drugs suppress seizures but do not have ability to cure epileptogenesis. The long term use of antiepileptic drugs is limited due to their adverse effects, withdrawal symptoms, deleterious interactions with other drugs and economic burden, especially in developing countries. Furthermore, some of the available antiepileptic drugs may even potentiate certain type of seizures. Several in vivo and in vitro animal models have been proposed and many new antiepileptic drugs have been marketed recently, but large numbers of patients are still pharmacoresistant. This review will highlight the difficulties in treatment and management of epilepsy and the limitations of available antiepileptic drugs and animal seizure models.
References
[1]
Elferink, J.G. Epilepsy and its treatment in the ancient cultures of America. Epilepsia？1999, 40, 1041–1046, doi:10.1111/j.1528-1157.1999.tb00815.x. 10403232
[2]
Satishchandra, P.; Gururaj, G.; Mohammed, Q.D.; Senanayake, N.; Silpakit, O. From Prejudice to Hope. Global Campaign against Epilepsy: Out of the Shadows; World Health Organization: Geneva, Switzerland, 2001; pp. 6–9.
[3]
Jackson, J.H. On the anatomical, physiological and pathological investigation of epilepsies. West Riding Lunatic Asylum Medical Reports？1873, 3, 315–339.
[4]
Penfield, W.; Jasper, H. Epilepsy and the Functional Anatomy of the Human Brain; Little, Brown and Company: Boston, MA, USA, 1954; pp. 3–40.
[5]
McNamara, J.O. Emerging insights into the genesis of epilepsy. Nature？1999, 399, A15–A22. 10392576
[6]
Noebels, J.L. The biology of epilepsy genes. Annu. Rev. Neurosci.？2003, 26, 599–625, doi:10.1146/annurev.neuro.26.010302.081210. 14527270
Bazil, C.W.; Pedley, T.A. Advances in the medical treatment of epilepsy. Annu. Rev. Med.？1998, 49, 135–162, doi:10.1146/annurev.med.49.1.135. 9509255
[9]
McCabe, P.H. New anti-epileptic drugs for the 21st century. Expert. Opin. Pharmacother.？2000, 1, 633–674, doi:10.1517/14656566.1.4.633. 11249508
[10]
Perucca, E.; French, J.; Bialer, M. Development of new antiepileptic drugs: challenges, incentives, and recent advances. Lancet Neurol.？2007, 6, 793–804, doi:10.1016/S1474-4422(07)70215-6. 17706563
[11]
Johannessen, L.C.; Patsalos, P.N. Drug interactions involving the new second- and third-generation antiepileptic drugs. Expert. Rev. Neurother.？2010, 10, 119–140, doi:10.1586/ern.09.136. 20021326
[12]
Heinemann, U.; Draguhn, A.; Ficker, E.; Stabel, J.; Zhang, C.L. Strategies for the development of drugs for pharmacoresistant epilepsies. Epilepsia？1994, 35 Suppl. 5, S10–S21. 8156973
[13]
Kupferberg, H. Animal models used in the screening of antiepileptic drugs. Epilepsia？2001, 42 Suppl. 4, 7–12. 11564118
[14]
Holmes, G.L.; Zhao, Q. Choosing the correct antiepileptic drugs: from animal studies to the clinic. Pediatr. Neurol.？2008, 38, 151–162, doi:10.1016/j.pediatrneurol.2007.09.008. 18279749
[15]
Bialer, M.; White, H.S. Key factors in the discovery and development of new antiepileptic drugs. Nat. Rev. Drug Discov.？2010, 9, 68–82, doi:10.1038/nrd2997. 20043029
[16]
Sander, J.W.; Shorvon, S.D. Epidemiology of the epilepsies. J. Neurol. Neurosurg. Psychiatry？1996, 61, 433–443, doi:10.1136/jnnp.61.5.433. 8965090
[17]
Brodie, M.J.; Shorvon, S.D.; Canger, R.; Halasz, P.; Johannessen, S.; Thompson, P.; Wieser, H.G.; Wolf, P. Commission on European affairs: appropriate standards of epilepsy care across Europe. ILEA. Epilepsia？1997, 38, 1245–1250, doi:10.1111/j.1528-1157.1997.tb01224.x. 9579928
[18]
Banerjee, P.N.; Filippi, D.; Allen, H.W. The descriptive epidemiology of epilepsy - A Review. Epilepsy Res.？2009, 85, 31–45, doi:10.1016/j.eplepsyres.2009.03.003. 19369037
[19]
Bell, G.S.; Sander, J.W. The epidemiology of epilepsy: the size of the problem. Seizure？2001, 10, 306–314, doi:10.1053/seiz.2001.0584. 11466029
[20]
Scott, R.A.; Lhatoo, S.D.; Sander, J.W. The treatment of epilepsy in developing countries: where do we go from here? Bull. World Health Organ.？2001, 79, 344–351. 11357214
[21]
Meinardi, H.; Scott, R.A.; Reis, R.; Sander, J.W. The treatment gap in epilepsy: the current situation and ways forward. Epilepsia？2001, 42, 136–149. 11207798
[22]
Mbuba, C.K.; Ngugi, A.K.; Newton, C.R.; Carter, J.A. The epilepsy treatment gap in developing countries: a systematic review of the magnitude, causes, and intervention strategies. Epilepsia？2008, 49, 1491–1503, doi:10.1111/j.1528-1167.2008.01693.x. 18557778
[23]
Radhakrishnan, K. Challenges in the management of epilepsy in resource-poor countries. Nat. Rev. Neurol.？2009, 5, 323–330, doi:10.1038/nrneurol.2009.53. 19455183
[24]
Senanayake, N.; Roman, G.C. Epidemiology of epilepsy in developing countries. Bull. World Health Organ.？1993, 71, 247–258. 8490989
[25]
Arida, R.M.; Scorza, C.A.; Schmidt, B.; de Albuquerque, M.; Cavalheiro, E.A.; Scorza, F.A. Physical activity in sudden unexpected death in epilepsy: much more than a simple sport. Neurosci. Bull.？2008, 24, 374–380, doi:10.1007/s12264-008-0805-z. 19037323
[26]
Johnston, A.; Smith, P. Sudden unexpected death in epilepsy. Expert. Rev. Neurother.？2007, 7, 1751–1761, doi:10.1586/14737175.7.12.1751. 18052767
[27]
Tomson, T.; Nashef, L.; Ryvlin, P. Sudden unexpected death in epilepsy: current knowledge and future directions. Lancet Neurol.？2008, 7, 1021–1031, doi:10.1016/S1474-4422(08)70202-3. 18805738
[28]
Leestma, J.E.; Walczak, T.; Hughes, J.R.; Kalelkar, M.B.; Teas, S.S. A prospective study on sudden unexpected death in epilepsy. Ann. Neurol.？1989, 26, 195–203, doi:10.1002/ana.410260203. 2774506
[29]
Langan, Y. Sudden unexpected death in epilepsy (SUDEP): risk factors and case control studies. Seizure.？2000, 9, 179–183, doi:10.1053/seiz.2000.0388. 10775513
[30]
Tomson, T.; Walczak, T.; Sillanpaa, M.; Sander, J.W. Sudden unexpected death in epilepsy: a review of incidence and risk factors. Epilepsia？2005, 46 Suppl. 11, 54–61. 16393182
[31]
Sander, J.W.; Hart, Y.M.; Johnson, A.L.; Shorvon, S.D. National general practice study of epilepsy: newly diagnosed epileptic seizures in a general population. Lancet？1990, 336, 1267–1271, doi:10.1016/0140-6736(90)92959-L. 1978113
[32]
Coppola, A.; Moshe, S.L. Why is the developing brain more susceptible to status epilepticus? Epilepsia？2009, 50 Suppl. 12, 25–26, doi:10.1111/j.1528-1167.2009.02371.x.
[33]
Wahab, A.; Albus, K.; Heinemann, U. Age and region specific effects of anticonvulsants and bumetanide on 4-aminopyridine induced seizure like events in hippocampal-entorhinal cortex slices. Epilepsia？2010. accepted.
[34]
Usta, I.M.; Adra, A.M.; Nassar, A.H. Ultrasonographic diagnosis of fetal seizures: a case report and review of the literature. BJOG.？2007, 114, 1031–1033, doi:10.1111/j.1471-0528.2007.01398.x. 17578473
[35]
Sheizaf, B.; Mazor, M.; Landau, D.; Burstein, E.; Bashiri, A.; Hershkovitz, R. Early sonographic prenatal diagnosis of seizures. Ultrasound Obstet. Gynecol.？2007, 30, 1007–1009, doi:10.1002/uog.5153. 17948231
[36]
Sun, Y.; Vestergaard, M.; Pedersen, C.B.; Christensen, J.; Basso, O.; Olsen, J. Gestational age, birth weight, intrauterine growth, and the risk of epilepsy. Am. J. Epidemiol.？2008, 167, 262–270. 18042672
[37]
Vestergaard, M.; Basso, O.; Henriksen, T.B.; Ostergaard, J.R.; Olsen, J. Risk factors for febrile convulsions. Epidemiology？2002, 13, 282–287, doi:10.1097/00001648-200205000-00008. 11964929
[38]
Albala, B.J.; Moshe, S.L.; Okada, R. Kainic-acid-induced seizures: a developmental study. Brain Res.？1984, 315, 139–148. 6722574
[39]
Sperber, E.F.; Haas, K.Z.; Stanton, P.K.; Moshe, S.L. Resistance of the immature hippocampus to seizure-induced synaptic reorganization. Brain Res. Dev. Brain Res.？1991, 60, 88–93, doi:10.1016/0165-3806(91)90158-F. 1717181
[40]
Stafstrom, C.E.; Thompson, J.L.; Holmes, G.L. Kainic acid seizures in the developing brain: status epilepticus and spontaneous recurrent seizures. Brain Res. Dev. Brain Res.？1992, 65, 227–236, doi:10.1016/0165-3806(92)90184-X. 1572066
[41]
Baram, T.Z.; Eghbal-Ahmadi, M.; Bender, R.A. Is neuronal death required for seizure-induced epileptogenesis in the immature brain? Prog. Brain Res.？2002, 135, 365–375. 12143355
[42]
Riviello, P.; de, R.L., I.; Holmes, G.L. Lack of cell loss following recurrent neonatal seizures. Brain Res. Dev. Brain Res.？2002, 135, 101–104. 11978398
[43]
Raol, Y.S.; Budreck, E.C.; Brooks-Kayal, A.R. Epilepsy after early-life seizures can be independent of hippocampal injury. Ann. Neurol.？2003, 53, 503–511, doi:10.1002/ana.10490. 12666118
Holmes, G.L. Effects of seizures on brain development: lessons from the laboratory. Pediatr. Neurol.？2005, 33, 1–11, doi:10.1016/j.pediatrneurol.2004.12.003. 15993318
[46]
Kramer, G. Epilepsy in the elderly: some clinical and pharmacotherapeutic aspects. Epilepsia？2001, 42 Suppl. 3, 55–59. 11520326
[47]
Bergey, G.K. Initial treatment of epilepsy: special issues in treating the elderly. Neurology？2004, 63, S40–S48, doi:10.1212/WNL.63.10_suppl_4.S40. 15557550
[48]
Regesta, G.; Tanganelli, P. Clinical aspects and biological bases of drug-resistant epilepsies. Epilepsy Res.？1999, 34, 109–122, doi:10.1016/S0920-1211(98)00106-5. 10210025
Leppik, I.E. Intractable epilepsy in adults. Epilepsy Res.？1992, 5 Suppl., 7–11.
[51]
Spencer, S.S. When should temporal-lobe epilepsy be treated surgically? Lancet Neurol.？2002, 1, 375–382, doi:10.1016/S1474-4422(02)00163-1. 12849399
[52]
Arts, W.F.; Brouwer, O.F.; Peters, A.C.; Stroink, H.; Peeters, E.A.; Schmitz, P.I.; van Donselaar, C.A.; Geerts, A.T. Course and prognosis of childhood epilepsy: 5-year follow-up of the Dutch study of epilepsy in childhood. Brain？2004, 127, 1774–1784, doi:10.1093/brain/awh200. 15201192
[53]
Wahab, A.; Albus, K.; Gabriel, S.; Heinemann, U. In search for models of pharmacoresistant epilepsy. A review. Epilepsia？2010, 51 Suppl. 3, 154–159. 20618423
[54]
Berg, A.T.; Shinnar, S. Relapse following discontinuation of antiepileptic drugs: a meta-analysis. Neurology？1994, 44, 601–608, doi:10.1212/WNL.44.4.601. 8164811
[55]
Specchio, L.M.; Tramacere, L.; La Neve, A.; Beghi, E. Discontinuing antiepileptic drugs in patients who are seizure free on monotherapy. J. Neurol. Neurosurg. Psychiatry？2002, 72, 22–25, doi:10.1136/jnnp.72.1.22. 11784819
[56]
Musicco, M.; Beghi, E.; Solari, A.; Viani, F. Treatment of first tonic-clonic seizure does not improve the prognosis of epilepsy. First seizure trial group (FIRST Group). Neurology？1997, 49, 991–998. 9339678
[57]
Berg, A.T.; Langfitt, J.; Shinnar, S.; Vickrey, B.G.; Sperling, M.R.; Walczak, T.; Bazil, C.; Pacia, S.V.; Spencer, S.S. How long does it take for partial epilepsy to become intractable? Neurology？2003, 60, 186–190. 12552028
[58]
Devinsky, O. Patients with refractory seizures. N. Engl. J. Med.？1999, 340, 1565–1570, doi:10.1056/NEJM199905203402008. 10332020
Heinemann, U. Basic mechanisms of partial epilepsies. Curr. Opin. Neurol.？2004, 17, 155–159, doi:10.1097/00019052-200404000-00012. 15021242
[62]
Schmidt, D.; Loscher, W. Drug resistance in epilepsy: putative neurobiologic and clinical mechanisms. Epilepsia？2005, 46, 858–877, doi:10.1111/j.1528-1167.2005.54904.x. 15946327
[63]
Remy, S.; Beck, H. Molecular and cellular mechanisms of pharmacoresistance in epilepsy. Brain？2006, 129, 18–35. 16317026
[64]
Raza, M.; Choudhary, M.I.; Atta-ur-Rahman. Medicinal plants with anticonvulsant activities. In Studies in Natural Product Chemistry; Atta-ur-Rahman, Ed.; Elsevier Science Publishers: Amsterdam, The Netherlands, 2000; Volume 22, pp. 507–553.
[65]
Schachter, S.C. Botanicals and herbs: a traditional approach to treating epilepsy. Neurotherapeutics？2009, 6, 415–420, doi:10.1016/j.nurt.2008.12.004. 19332338
[66]
Krall, R.L.; Penry, J.K.; Kupferberg, H.J.; Swinyard, E.A. Antiepileptic drug development: i. History and a program for progress. Epilepsia？1978, 19, 393–408. 359324
[67]
Shorvon, S.D. Drug treatment of epilepsy in the century of the ILAE: the first 50 years, 1909-1958. Epilepsia？2009, 50 Suppl. 3, 69–92. 19702737
[68]
Hauptmann, A. Luminal bei epilepsie. Münchener Medizinische Wochenschrift？1912, 59, 1907–1909.
[69]
Wilder, R.M. Effects of ketonuria on the course of epilepsy. Mayo Clin. Bull.？1921, 2, 307–314.
[70]
Lennox, W.G. Ketogenic diet in the treatment of epilepsy. N. Engl. J. Med.？1928, 199, 74–75, doi:10.1056/NEJM192807121990206.
[71]
Wheless, J.W. History of the ketogenic diet. Epilepsia？2008, 49 Suppl 8, 3–5. 24888711
[72]
Kossoff, E.H.; Rho, J.M. Ketogenic diets: evidence for short- and long-term efficacy. Neurotherapeutics？2009, 6, 406–414, doi:10.1016/j.nurt.2009.01.005. 19332337
[73]
Geyelin, H.R. Fasting as a method for treating epilepsy. Med. Rec.？1921, 99, 1037–1039.
[74]
Putnam, T.J.; Merritt, H.H. Experimental determination of the anticonvulsant properties of some phenyl derivatives. Science？1937, 85, 525–526, doi:10.1126/science.85.2213.525. 17750072
[75]
Merritt, H.H.; Putnam, T.J. A new series of anticonvulsant drugs tested by experiments on animals. Arch. Neurol. Psychiatry？1938, 39, 1003–1015, doi:10.1001/archneurpsyc.1938.02270050129007.
[76]
Merritt, H.H.; Putnam, T.J. Sodium diphenyl hydantoinate in the treatment of convulsive disorders. JAMA？1938, 111, 1068–1073, doi:10.1001/jama.1938.02790380010004.
[77]
Richards, R.K.; Everett, G.M. Analgesic and anticonvulsant properties of 3,5,5-trimethyloxazolidine-2,4-dione (Tridione). Fed. Proc.？1944, 3, 39.
[78]
Lennox, W.G. The petit mal epilepsies: their treatment with Tridione. JAMA？1945, 129, 1069–1074, doi:10.1001/jama.1945.02860500001001.
[79]
Rogvi-Hansen, B.; Gram, L. Adverse effects of established and new antiepileptic drugs: an attempted comparison. Pharmacol. Ther.？1995, 68, 425–434, doi:10.1016/0163-7258(95)02014-4. 8788565
[80]
Leppik, I.E. Issues in the treatment of epilepsy. Epilepsia？2001, 42 Suppl 4, 1–6. 24779523
Schindler, W.; H？fliger, F. über Derivate des Iminodibenzyls. Helvetica Chimica Acta？1954, 37, 472–483, doi:10.1002/hlca.19540370211.
[83]
Meunier, H.; Carraz, G.; Neunier, Y.; Eymard, P.; Aimard, M. [Pharmacodynamic properties of n-dipropylacetic acid.]. Therapie？1963, 18, 435–438. 13935231
[84]
Perucca, E. What is the promise of new antiepileptic drugs in status epilepticus? Focus on brivaracetam, carisbamate, lacosamide, NS-1209, and topiramate. Epilepsia？2009, 50 Suppl. 12, 49–50, doi:10.1111/j.1528-1167.2009.02366.x.
[85]
Stefan, H.; Halasz, P.; Gil-Nagel, A.; Shorvon, S.; Bauer, G.; Ben Menachem, E.; Perucca, E.; Wieser, H.G.; Steinlein, O. Recent advances in the diagnosis and treatment of epilepsy. Eur. J. Neurol.？2001, 8, 519–539, doi:10.1046/j.1468-1331.2001.00251.x. 11784335
[86]
Stacey, W.C.; Litt, B. Technology insight: neuroengineering and epilepsy-designing devices for seizure control. Nat. Clin. Pract. Neurol.？2008, 4, 190–201. 18301414
[87]
Shinnar, S.; Berg, A.T. Does antiepileptic drug therapy prevent the development of "chronic" epilepsy? Epilepsia？1996, 37, 701–708, doi:10.1111/j.1528-1157.1996.tb00639.x. 8764806
[88]
Temkin, N.R. Antiepileptogenesis and seizure prevention trials with antiepileptic drugs: meta-analysis of controlled trials. Epilepsia？2001, 42, 515–524, doi:10.1046/j.1528-1157.2001.28900.x. 11440347
[89]
Schachter, S.C. Current evidence indicates that antiepileptic drugs are anti-ictal, not antiepileptic. Epilepsy Res.？2002, 50, 67–70, doi:10.1016/S0920-1211(02)00069-4. 12151118
[90]
Macleod, S.; Appleton, R.E. The new antiepileptic drugs. Arch. Dis. Child Educ. Pract. Ed.？2007, 92, 182–188, doi:10.1136/adc.2007.106880. 18032714
[91]
Marson, A.G.; Kadir, Z.A.; Hutton, J.L.; Chadwick, D.W. The new antiepileptic drugs: a systematic review of their efficacy and tolerability. Epilepsia？1997, 38, 859–880, doi:10.1111/j.1528-1157.1997.tb01251.x. 9579887
Brodie, M.J.; Dichter, M.A. Antiepileptic drugs. N. Engl. J. Med.？1996, 334, 168–175, doi:10.1056/NEJM199601183340308. 8531974
[98]
Schachter, S.C. Currently available antiepileptic drugs. Neurotherapeutics？2007, 4, 4–11, doi:10.1016/j.nurt.2006.11.005. 17199013
[99]
Browne, T.R.; Penry, J.K. Benzodiazepines in the treatment of epilepsy. A review. Epilepsia？1973, 14, 277–310, doi:10.1111/j.1528-1157.1973.tb03965.x. 4204764
[100]
Sander, J.W. The use of antiepileptic drugs-principles and practice. Epilepsia？2004, 45 Suppl. 6, 28–34, doi:10.1111/j.0013-9580.2004.455005.x.
Bjornsson, E. Hepatotoxicity associated with antiepileptic drugs. Acta Neurol. Scand.？2008, 118, 281–290. 18341684
[103]
Biton, V. Effect of antiepileptic drugs on bodyweight: overview and clinical implications for the treatment of epilepsy. CNS Drugs？2003, 17, 781–791, doi:10.2165/00023210-200317110-00002. 12921491
[104]
Ben Menachem, E. Weight issues for people with epilepsy-a review. Epilepsia？2007, 48 Suppl. 9, 42–45, doi:10.1111/j.1528-1167.2007.01402.x.
[105]
Asconape, J.J. Some common issues in the use of antiepileptic drugs. Semin. Neurol.？2002, 22, 27–39, doi:10.1055/s-2002-33046. 12170391
[106]
Wilby, J.; Kainth, A.; Hawkins, N.; Epstein, D.; McIntosh, H.; McDaid, C.; Mason, A.; Golder, S.; O'Meara, S.; Sculpher, M.; Drummond, M.; Forbes, C. Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation. Health Technol. Assess.？2005, 9, 1–iv. 16303099
[107]
Zaccara, G.; Franciotta, D.; Perucca, E. Idiosyncratic adverse reactions to antiepileptic drugs. Epilepsia？2007, 48, 1223–1244, doi:10.1111/j.1528-1167.2007.01041.x. 17386054
Van Amelsvoort, T.; Bakshi, R.; Devaux, C.B.; Schwabe, S. Hyponatremia associated with carbamazepine and oxcarbazepine therapy: a review. Epilepsia？1994, 35, 181–188, doi:10.1111/j.1528-1157.1994.tb02930.x. 8112243
[110]
Buehler, B.A.; Delimont, D.; van Waes, M.; Finnell, R.H. Prenatal prediction of risk of the fetal hydantoin syndrome. N. Engl. J. Med.？1990, 322, 1567–1572, doi:10.1056/NEJM199005313222204. 2336087
[111]
Zahn, C. Neurologic care of pregnant women with epilepsy. Epilepsia？1998, 39 Suppl. 8, S26–S31, doi:10.1111/j.1528-1157.1998.tb02604.x.
[112]
Holmes, L.B.; Harvey, E.A.; Coull, B.A.; Huntington, K.B.; Khoshbin, S.; Hayes, A.M.; Ryan, L.M. The teratogenicity of anticonvulsant drugs. N. Engl. J. Med.？2001, 344, 1132–1138, doi:10.1056/NEJM200104123441504. 11297704
[113]
Meador, K.J.; Baker, G.A.; Finnell, R.H.; Kalayjian, L.A.; Liporace, J.D.; Loring, D.W.; Mawer, G.; Pennell, P.B.; Smith, J.C.; Wolff, M.C. In utero antiepileptic drug exposure: fetal death and malformations. Neurology？2006, 67, 407–412, doi:10.1212/01.wnl.0000227919.81208.b2. 16894099
[114]
Tatum, W.O. Use of antiepileptic drugs in pregnancy. Expert. Rev. Neurother.？2006, 6, 1077–1086, doi:10.1586/14737175.6.7.1077. 16831120
Gayatri, N.A.; Livingston, J.H. Aggravation of epilepsy by anti-epileptic drugs. Dev. Med. Child Neurol.？2006, 48, 394–398, doi:10.1017/S0012162206000843. 16608550
[119]
Perucca, E.; Gram, L.; Avanzini, G.; Dulac, O. Antiepileptic drugs as a cause of worsening seizures. Epilepsia？1998, 39, 5–17, doi:10.1111/j.1528-1157.1998.tb01268.x. 9578007
[120]
Guerrini, R.; Belmonte, A.; Genton, P. Antiepileptic drug-induced worsening of seizures in children. Epilepsia？1998, 39 Suppl. 3, S2–S10. 9915614
[121]
Tanaka, E. Clinically significant pharmacokinetic drug interactions between antiepileptic drugs. J. Clin. Pharm. Ther.？1999, 24, 87–92, doi:10.1046/j.1365-2710.1999.00201.x. 10380060
[122]
Leppik, I.E.; Schmidt, D. Consensus statement on compliance in epilepsy. Epilepsy Res. Suppl？1988, 1, 179–182. 3072189
[123]
Cramer, J.A.; Mattson, R.H.; Prevey, M.L.; Scheyer, R.D.; Ouellette, V.L. How often is medication taken as prescribed? A novel assessment technique. JAMA？1989, 261, 3273–3277, doi:10.1001/jama.1989.03420220087032. 2716163
[124]
Cramer, J.; Vachon, L.; Desforges, C.; Sussman, N.M. Dose frequency and dose interval compliance with multiple antiepileptic medications during a controlled clinical trial. Epilepsia？1995, 36, 1111–1117, doi:10.1111/j.1528-1157.1995.tb00469.x. 7588455
[125]
Patsalos, P.N.; Berry, D.J.; Bourgeois, B.F.; Cloyd, J.C.; Glauser, T.A.; Johannessen, S.I.; Leppik, I.E.; Tomson, T.; Perucca, E. Antiepileptic drugs--best practice guidelines for therapeutic drug monitoring: a position paper by the subcommission on therapeutic drug monitoring, ILAE Commission on Therapeutic Strategies. Epilepsia？2008, 49, 1239–1276, doi:10.1111/j.1528-1167.2008.01561.x. 18397299
[126]
Onat, F.; Ozkara, C. Adverse effects of new antiepileptic drugs. Drugs Today (Barc.)？2004, 40, 325–342, doi:10.1358/dot.2004.40.4.820079. 15190386
[127]
Sabers, A.; Gram, L. Newer anticonvulsants: comparative review of drug interactions and adverse effects. Drugs？2000, 60, 23–33, doi:10.2165/00003495-200060010-00003. 10929928
White, H.S. Clinical significance of animal seizure models and mechanism of action studies of potential antiepileptic drugs. Epilepsia？1997, 38 Suppl. 1, S9–S17. 19909336
[132]
Everett, G.M.; Richards, R.K. Comparative anticonvulsive action of 3,5,5-trimethyloxazolidine-2,4-dione (tridione), dilantin, and phenobarbital. J. Pharmacol. Exp. Ther.？1944, 81, 402–407.
[133]
Swinyard, E.A. Laboratory evaluation of antiepileptic drugs. Review of laboratory methods. Epilepsia？1969, 10, 107–119, doi:10.1111/j.1528-1157.1969.tb03838.x. 4895510
[134]
Krall, R.L.; Penry, J.K.; White, B.G.; Kupferberg, H.J.; Swinyard, E.A. Antiepileptic Drug Development: II. Anticonvulsant Drug Screening. Epilepsia？1978, 19, 409–428. 699894
[135]
White, H.S. Preclinical development of antiepileptic drugs: past, present, and future directions. Epilepsia？2003, 44 Suppl. 7, 2–8. 14641565
[136]
Smith, M.; Wilcox, K.S.; White, H.S. Discovery of antiepileptic drugs. Neurotherapeutics？2007, 4, 12–17, doi:10.1016/j.nurt.2006.11.009. 17199014
[137]
Miller, A.A.; Wheatley, P.; Sawyer, D.A.; Baxter, M.G.; Roth, B. Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: I. Anticonvulsant profile in mice and rats. Epilepsia？1986, 27, 483–489, doi:10.1111/j.1528-1157.1986.tb03572.x. 3757935
[138]
Ferrie, C.D.; Robinson, R.O.; Knott, C.; Panayiotopoulos, C.P. Lamotrigine as an add-on drug in typical absence seizures. Acta Neurol. Scand.？1995, 91, 200–202. 7793236
[139]
Glauser, T.A.; Cnaan, A.; Shinnar, S.; Hirtz, D.G.; Dlugos, D.; Masur, D.; Clark, P.O.; Capparelli, E.V.; Adamson, P.C. Ethosuximide, valproic acid, and lamotrigine in childhood absence epilepsy. N. Engl. J. Med.？2010, 362, 790–799. 20200383
[140]
Gower, A.J.; Noyer, M.; Verloes, R.; Gobert, J.; Wulfert, E. UCB L059, a novel anti-convulsant drug: pharmacological profile in animals. Eur. J. Pharmacol.？1992, 222, 193–203, doi:10.1016/0014-2999(92)90855-X. 1451732
[141]
Gower, A.J.; Hirsch, E.; Boehrer, A.; Noyer, M.; Marescaux, C. Effects of levetiracetam, a novel antiepileptic drug, on convulsant activity in two genetic rat models of epilepsy. Epilepsy Res.？1995, 22, 207–213, doi:10.1016/0920-1211(95)00077-1. 8991787
[142]
Klitgaard, H.; Matagne, A.; Gobert, J.; Wulfert, E. Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur. J. Pharmacol.？1998, 353, 191–206, doi:10.1016/S0014-2999(98)00410-5. 9726649
[143]
Leschinger, A.; Stabel, J.; Igelmund, P.; Heinemann, U. Pharmacological and electrographic properties of epileptiform activity induced by elevated K+ and lowered Ca2+ and Mg2+ concentration in rat hippocampal slices. Exp. Brain Res.？1993, 96, 230–240. 7903641
[144]
Yaari, Y.; Konnerth, A.; Heinemann, U. Spontaneous epileptiform activity of ca1 hippocampal neurons in low extracellular calcium solutions. Exp. Brain Res.？1983, 51, 153–156. 6884463
[145]
Mody, I.; Lambert, J.D.; Heinemann, U. Low extracellular magnesium induces epileptiform activity and spreading depression in rat hippocampal slices. J. Neurophysiol.？1987, 57, 869–888. 3031235
[146]
Fueta, Y.; Avoli, M. Effects of antiepileptic drugs on 4-aminopyridine-induced epileptiform activity in young and adult rat hippocampus. Epilepsy Res.？1992, 12, 207–215, doi:10.1016/0920-1211(92)90075-5. 1396546
[147]
Bruckner, C.; Heinemann, U. Effects of standard anticonvulsant drugs on different patterns of epileptiform discharges induced by 4-aminopyridine in combined entorhinal cortex-hippocampal slices. Brain Res.？2000, 859, 15–20, doi:10.1016/S0006-8993(99)02348-3. 10720610
[148]
Stasheff, S.F.; Bragdon, A.C.; Wilson, W.A. Induction of epileptiform activity in hippocampal slices by trains of electrical stimuli. Brain Res.？1985, 344, 296–302, doi:10.1016/0006-8993(85)90807-8. 4041878
[149]
Higashima, M.; Kinoshita, H.; Yamaguchi, N.; Koshino, Y. Activation of gabaergic function necessary for afterdischarge generation in rat hippocampal slices. Neurosci. Lett.？1996, 207, 101–104, doi:10.1016/0304-3940(96)12496-4. 8731431
[150]
Isomura, Y.; Fujiwara-Tsukamoto, Y.; Takada, M. A network mechanism underlying hippocampal seizure-like synchronous oscillation. Neurosci. Res.？2008, 61, 227–233, doi:10.1016/j.neures.2008.04.002. 18457889
[151]
Wahab, A.; Albus, K.; Heinemann, U. Drug refractoriness of epileptiform activity in organotypic hippocampal slice cultures depends on the mode of provocation. Epilepsy Res.？2010. in press.
[152]
Loscher, W.; Rundfeldt, C.; Honack, D. Pharmacological characterization of phenytoin-resistant amygdala-kindled rats, a new model of drug-resistant partial epilepsy. Epilepsy Res.？1993, 15, 207–219, doi:10.1016/0920-1211(93)90058-F. 8223417
[153]
Postma, T.; Krupp, E.; Li, X.L.; Post, R.M.; Weiss, S.R. Lamotrigine treatment during amygdala-kindled seizure development fails to inhibit seizures and diminishes subsequent anticonvulsant efficacy. Epilepsia？2000, 41, 1514–1521, doi:10.1111/j.1499-1654.2000.001514.x. 11114208
[154]
Brown, W.C.; Schiffman, D.O.; Swinyard, E.A.; Goodman, L.S. Comparative assay of an antiepileptic drugs by psychomotor seizure test and minimal electroshock threshold test. J. Pharmacol. Exp. Ther.？1953, 107, 273–283. 13035666
[155]
Barton, M.E.; Klein, B.D.; Wolf, H.H.; White, H.S. Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy. Epilepsy Res.？2001, 47, 217–227, doi:10.1016/S0920-1211(01)00302-3. 11738929
[156]
Leite, J.P.; Cavalheiro, E.A. Effects of conventional antiepileptic drugs in a model of spontaneous recurrent seizures in rats. Epilepsy Res.？1995, 20, 93–104, doi:10.1016/0920-1211(94)00070-D. 7750514
[157]
Grabenstatter, H.L.; Ferraro, D.J.; Williams, P.A.; Chapman, P.L.; Dudek, F.E. Use of chronic epilepsy models in antiepileptic drug discovery: the effect of topiramate on spontaneous motor seizures in rats with kainate-induced epilepsy. Epilepsia？2005, 46, 8–14. 16393171
[158]
van Vliet, E.A.; van Schaik, R.; Edelbroek, P.M.; Redeker, S.; Aronica, E.; Wadman, W.J.; Marchi, N.; Vezzani, A.; Gorter, J.A. Inhibition of the multidrug transporter p-glycoprotein improves seizure control in phenytoin-treated chronic epileptic rats. Epilepsia？2006, 47, 672–680, doi:10.1111/j.1528-1167.2006.00496.x. 16650133
[159]
Smyth, M.D.; Barbaro, N.M.; Baraban, S.C. Effects of antiepileptic drugs on induced epileptiform activity in a rat model of dysplasia. Epilepsy Res.？2002, 50, 251–264, doi:10.1016/S0920-1211(02)00051-7. 12200216
[160]
Brückner, C.; Stenkamp, K.; Meierkord, H.; Heinemann, U. Epileptiform discharges induced by combined application of bicuculline and 4-aminopyridine are resistant to standard anticonvulsants in slices of rats. Neurosci. Lett.？1999, 268, 163–165, doi:10.1016/S0304-3940(99)00341-9. 10406030
[161]
Dreier, J.P.; Heinemann, U. Late low magnesium-induced epileptiform activity in rat entorhinal cortex slices becomes insensitive to the anticonvulsant valproic acid. Neurosci. Lett.？1990, 119, 68–70, doi:10.1016/0304-3940(90)90757-Z. 1982961
[162]
Zhang, C.L.; Dreier, J.P.; Heinemann, U. Paroxysmal epileptiform discharges in temporal lobe slices after prolonged exposure to low magnesium are resistant to clinically used anticonvulsants. Epilepsy Res.？1995, 20, 105–111, doi:10.1016/0920-1211(94)00067-7. 7750506
[163]
Albus, K.; Wahab, A.; Heinemann, U. Standard antiepileptic drugs fail to block epileptiform activity in rat organotypic hippocampal slice cultures. Br. J. Pharm.？2008, 154, 709–724, doi:10.1038/bjp.2008.112.
[164]
Wahab, A.; Heinemann, U.; Albus, K. Effects of gamma-aminobutyric acid (GABA) agonists and a GABA uptake inhibitor on pharmacoresistant seizure like events in organotypic hippocampal slice cultures. Epilepsy Res.？2009, 86, 113–123, doi:10.1016/j.eplepsyres.2009.05.008. 19535226
[165]
Quilichini, P.P.; Diabira, D.; Chiron, C.; Milh, M.; Ben Ari, Y.; Gozlan, H. Effects of antiepileptic drugs on refractory seizures in the intact immature corticohippocampal formation in vitro. Epilepsia？2003, 44, 1365–1374, doi:10.1046/j.1528-1157.2003.19503.x. 14636342
[166]
Wozny, C.; Kivi, A.; Lehmann, T.N.; Dehnicke, C.; Heinemann, U.; Behr, J. Comment on "on the origin of interictal activity in human temporal lobe epilepsy in vitro". Science？2003, 301, 463. 12881553
[167]
Remy, S.; Gabriel, S.; Urban, B.W.; Dietrich, D.; Lehmann, T.N.; Elger, C.E.; Heinemann, U.; Beck, H. A novel mechanism underlying drug resistance in chronic epilepsy. Ann. Neurol.？2003, 53, 469–479, doi:10.1002/ana.10473. 12666114
[168]
Gabriel, S.; Njunting, M.; Pomper, J.K.; Merschhemke, M.; Sanabria, E.R.; Eilers, A.; Kivi, A.; Zeller, M.; Meencke, H.J.; Cavalheiro, E.A.; Heinemann, U.; Lehmann, T.N. Stimulus and potassium-induced epileptiform activity in the human dentate gyrus from patients with and without hippocampal sclerosis. J. Neurosci.？2004, 24, 10416–10430, doi:10.1523/JNEUROSCI.2074-04.2004. 15548657
[169]
Jandova, K.; Pasler, D.; Antonio, L.L.; Raue, C.; Ji, S.; Njunting, M.; Kann, O.; Kovacs, R.; Meencke, H.J.; Cavalheiro, E.A.; Heinemann, U.; Gabriel, S.; Lehmann, T.N. Carbamazepine-resistance in the epileptic dentate gyrus of human hippocampal slices. Brain？2006, 129, 3290–3306, doi:10.1093/brain/awl218. 16951410
[170]
Oby, E.; Caccia, S.; Vezzani, A.; Moeddel, G.; Hallene, K.; Guiso, G.; Said, T.; Bingaman, W.; Marchi, N.; Baumgartner, C.; Pirker, S.; Czech, T.; Lo, R.G.; Janigro, D. In vitro responsiveness of human-drug-resistant tissue to antiepileptic drugs: insights into the mechanisms of pharmacoresistance. Brain Res.？1086, 201–213.
[171]
Snead, O.C., 3rd. Pharmacological models of generalized absence seizures in rodents. J. Neural Transm. Suppl.？1992, 35, 7–19. 1380980
[172]
Jefferys, J.G. Models and mechanisms of experimental epilepsies. Epilepsia？2003, 44 Suppl. 12, 44–50. 24621319
[173]
McNamara, J.O. Development of new pharmacological agents for epilepsy: lessons from the kindling model. Epilepsia？1989, 30, S13–S18, doi:10.1111/j.1528-1157.1989.tb05809.x. 2776709
[174]
Turski, W.A.; Cavalheiro, E.A.; Bortolotto, Z.A.; Mello, L.M.; Schwarz, M.; Turski, L. Seizures produced by pilocarpine in mice: a behavioral, electroencephalographic and morphological analysis. Brain Res.？1984, 321, 237–253, doi:10.1016/0006-8993(84)90177-X. 6498517
[175]
Cavalheiro, E.A.; Leite, J.P.; Bortolotto, Z.A.; Turski, W.A.; Ikonomidou, C.; Turski, L. Long-term effects of pilocarpine in rats: structural damage of the brain triggers kindling and spontaneous recurrent seizures. Epilepsia？1991, 32, 778–782, doi:10.1111/j.1528-1157.1991.tb05533.x. 1743148
Curia, G.; Longo, D.; Biagini, G.; Jones, R.S.; Avoli, M. The pilocarpine model of temporal lobe epilepsy. J. Neurosci. Methods？2008, 172, 143–157, doi:10.1016/j.jneumeth.2008.04.019. 18550176
[178]
Johannessen, L.C.; Johannessen, S.I. Pharmacological management of epilepsy: recent advances and future prospects. Drugs？2008, 68, 1925–1939, doi:10.2165/00003495-200868140-00001. 18778117
[179]
Johannessen, L.C. Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy. CNS Drugs？2008, 22, 27–47, doi:10.2165/00023210-200822010-00003. 18072813
[180]
Perucca, E. An introduction to antiepileptic drugs. Epilepsia？2005, 46 Suppl. 4, 31–37, doi:10.1111/j.1528-1167.2005.463007.x.
[181]
Wetter, T.C.; Winkelmann, J.; Eisensehr, I. Current treatment options for restless legs syndrome. Expert. Opin. Pharmacother.？2003, 4, 1727–1738, doi:10.1517/14656566.4.10.1727. 14521483
[182]
Lejoyeux, M.; Solomon, J.; Ades, J. Benzodiazepine treatment for alcohol-dependent patients. Alcohol Alcohol？1998, 33, 563–575, doi:10.1093/alcalc/33.6.563. 9872344
[183]
Dworkin, R.H.; O'Connor, A.B.; Audette, J.; Baron, R.; Gourlay, G.K.; Haanpaa, M.L.; Kent, J.L.; Krane, E.J.; Lebel, A.A.; Levy, R.M.; Mackey, S.C.; Mayer, J.; Miaskowski, C.; Raja, S.N.; Rice, A.S.; Schmader, K.E.; Stacey, B.; Stanos, S.; Treede, R.D.; Turk, D.C.; Walco, G.A.; Wells, C.D. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin. Proc.？2010, 85, S3–S14. 21106869
[184]
Pappagallo, M. Newer antiepileptic drugs: possible uses in the treatment of neuropathic pain and migraine. Clin. Ther.？2003, 25, 2506–2538, doi:10.1016/S0149-2918(03)80314-4. 14667954
[185]
Evins, A.E. Efficacy of newer anticonvulsant medications in bipolar spectrum mood disorders. J. Clin. Psychiatry？2003, 64 Suppl 8, 9–14. 24813261
[186]
Keck, P.E., Jr.; Strawn, J.R.; McElroy, S.L. Pharmacologic treatment considerations in co-occurring bipolar and anxiety disorders. J. Clin. Psychiatry？2006, 67 Suppl. 1, 8–15, doi:10.4088/JCP.0906e08.
[187]
Vikelis, M.; Rapoport, A.M. Role of antiepileptic drugs as preventive agents for migraine. CNS Drugs？2010, 24, 21–33, doi:10.2165/11310970-000000000-00000. 20030417
